Skip to main content

FDA Approves Imuldosa

FDA Approves Imuldosa (ustekinumab-srlf), a Biosimilar to Stelara

RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ -- Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that the U.S. Food and Drug Administration (FDA) has approved Imuldosa (ustekinumab-srlf), a biosimilar to Stelara (ustekinumab), for the treatment of chronic inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The FDA approved Imuldosa for all indications of its reference medicine, Stelara.

Stelara 's annual worldwide sales in 2023 amounted to $10.86 billion, underscoring the significant market potential for Imuldosa . Accord anticipates a commercial launch of Imuldosa in the first half of 2025.

"For Accord BioPharma, this is another step forward in our efforts to deliver affordable treatments and satisfy patient needs," said Chrys Kokino, U.S. president of Accord. "The approval of Imuldosa , our second biosimilar, is evidence of our growing momentum in the industry and our leadership in supporting families with accessible options to address urgent and critical medical conditions."

For the millions of Americans living with chronic inflammatory conditions, which can be painful, and also can have a significant impact on quality of life, emotional well-being, and self-image, Imuldosa has the potential to be an affordable treatment option that provides similar benefits to the current standard of care. It also marks the second biosimilar to be FDA-approved from Accord BioPharma, arriving shortly after the approval of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin®, earlier this year.

FDA approval of Imuldosa was granted based on a comprehensive clinical development program. The data showed that Imuldosa is similar to its reference product Stelara in terms of pharmacokinetic characteristics, safety, tolerability, and efficacy, and that Imuldosa adheres to current biosimilar guidance from the FDA.

"We're proud to add Imuldosa to our U.S. biosimilar portfolio, which represents an affordable treatment option for patients living with painful inflammatory conditions. It is Accord BioPharma's goal to go beyond biology and continuously work to provide affordable world-class treatments to patients," said Binish Chudgar, vice chairman and managing director, Intas Pharmaceuticals. "As our presence in the biosimilar market continues to grow, so does our commitment to offering high quality, affordable alternatives to reference drugs, so that more patients can access the treatments they need to thrive."

Imuldosa was initially developed as DMB-3115 in 2013 by Dong-A Socio Holdings and Meiji Seika Pharma. In 2021, Intas Pharmaceuticals acquired exclusive commercialization rights to DMB-3115 through a license agreement. As a global subsidiary of Intas Pharmaceuticals, Accord BioPharma will be responsible for U.S. commercialization of Imuldosa .

In addition to Imuldosa and HERCESSI, Accord BioPharma is planning on introducing several additional biosimilars to the U.S. market during the next five years.

Imuldosa Indications and Important Safety Information

Infections

Theoretical Risk for Vulnerability to Particular Infections

Pre-treatment Evaluation for Tuberculosis

Malignancies

Hypersensitivity Reactions

Posterior Reversible Encephalopathy Syndrome (PRES)

Immunizations

Noninfectious Pneumonia

Most Common Adverse Reactions
The most common adverse reactions associated with ustekinumab products are:

INDICATIONS
Imuldosa is a human interleukin-12 and -23 antagonist indicated for the treatment of:
Adult patients with:

Pediatric patients 6 years and older with:

For more information, please see the full Prescribing Information.

About Accord BioPharma
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patients' perspective and develop high-quality therapies that impact patients' lives. Accord BioPharma believes in the ability of biosimilars to increase access and options for patients and deliver savings to the U.S. healthcare system, and is striving to offer one of the deepest biosimilar portfolios in the industry. For more information, visit AccordBioPharma.com.

References:
1. Imuldosa (ustekinumab-srlf). Prescribing Information. Accord BioPharma; October 2024.
2. Johnson & Johnson Reports: Q4 and Full-Year 2023 Results.
3. Pahwa R, Goyal A, Jialal I. Chronic Inflammation. StatPearls Publishing; 2023.
4. Beese SE, Harris IM, Dretzke J, Moore D. Body image dissatisfaction in patients with inflammatory bowel disease: a systematic review. BMJ Open Gastroenterol. 2019 Feb 16;6(1):e000255.
5. Accord BioPharma. Data on file.

Stelara ® is a registered trademark of Janssen Biotech Inc.

SOURCE Accord BioPharma

Imuldosa (ustekinumab-srlf) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.